United States Patent 7,973,031 Scope and Claims Analysis for Oral Formula (VII) in FLT3-Driven Acute Myeloid Leukemia
Executive summary: U.S. Patent 7,973,031 claims methods of treating acute myeloid leukemia (AML) by orally administering compound of formula (VII), including dosing “up to 150 mg per day”, with dependent claim narrowing to FLT3 deregulated disease and specific oral delivery forms (microemulsion, soft gel, solid dispersion). The estate is centered on method-of-treatment + compound formula + oral exposure parameters rather than broad composition claims alone, creating a direct infringement pathway for oral AML therapy using the same structural entity (VII) within the claimed dose and (for dependent claims) formulation archetypes.
What does U.S. Patent 7,973,031 claim for acute myeloid leukemia treatment by oral dosing?
Short answer: The patent claims a method: treat AML in a mammal by orally administering a therapeutically effective amount of compound of formula (VII), defined as N-[(9S,10R,11R,13R)-…-benzodiazonin-11-yl]-N-methylbenzamide (and salts), at up to 150 mg per day.
Claim 1 core elements (independent)
Claim 1 is structured as a classic method-of-use claim with the following mandatory limitations:
- Subject condition: “a mammal suffering from acute myeloid leukemia.”
- Route: “orally administering” (oral administration).
- Active definition: compound of formula (VII):
- “N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methylbenzamide”
- plus “or a salt thereof.”
- Dose ceiling: “a therapeutically effective amount of up to 150 mg per day.”
Practical consequence for infringement: A generic or competitor product must avoid simultaneously meeting:
- the AML treatment use,
- oral administration, and
- the compound identity (formula VII) (or a salt),
- and dose regimen fitting ≤150 mg/day as claimed (or argue out of “up to” construction based on claim construction facts, which is typically narrower for “up to” language).
What is covered beyond “treating AML”?
Claim 1 does not require biomarkers, mutation status, or specific staging. Its scope is broad across AML subtypes so long as the patient “suffers from” AML and the oral administration uses the claimed compound at or within the “up to 150 mg/day” cap.
How does claim scope narrow when AML is defined by FLT3 deregulated tyrosine kinase activity?
Short answer: Claim 2 narrows claim 1 to AML cases “characterized by deregulated FLT3 receptor tyrosine kinase activity.”
Claim 2 dependency
Claim 2 incorporates claim 1 and adds a disease characterization limitation:
- AML is characterized by deregulated FLT3 receptor tyrosine kinase activity.
Impact on claim breadth:
- Claim 1 covers AML generally.
- Claim 2 covers a molecularly defined subset. This matters for:
- labeling arguments (if a therapy is indicated only for FLT3-mutant AML),
- marketing and prescriber instructions,
- and evidentiary proof in litigation (biomarker status).
How much is gained by the FLT3 limitation?
It potentially strengthens enforceability by tethering the use to a specific mechanistic target and patient subgroup. But it can also reduce the number of scenarios where claim 2 is relevant if competitors pursue non-FLT3-directed AML regimens or patient populations without FLT3 deregulation.
Which oral formulation types are protected: microemulsion, soft gel, or solid dispersion?
Short answer: Claim 3 protects administration of formula (VII) as a microemulsion, soft gel, or solid dispersion. Claims 4 and 6 further narrow to microemulsion.
Claim 3: formulation class restriction
Claim 3 depends from claim 1 and requires:
- the compound of formula VII is administered as a:
- microemulsion, soft gel, or solid dispersion.
Key scope feature: Claim 3 is not limited to a single dosage form. It covers three oral delivery archetypes in one dependent claim, giving the patent a formulation-agnostic enforcement entry across common solubilization and oral bioavailability technologies.
Claims 4 and 6: microemulsion-specific sub-scope
- Claim 4: depends from claim 3 and requires administration as a microemulsion.
- Claim 6: depends from claim 5 and also requires microemulsion.
Claim 5: combining FLT3 + formulation
Claim 5 depends from claim 3 (thus incorporating formulation types) and adds FLT3 deregulation:
- the compound is administered as microemulsion/soft gel/solid dispersion, and
- the AML is characterized by deregulated FLT3 activity.
Then claim 6 further tightens to microemulsion.
Practical implication: A defendant using microemulsion and treating FLT3-deregulated AML is positioned squarely within claim 6. A defendant using soft gels or solid dispersions may avoid claim 4/6 but may still hit claim 3/5 depending on their disease characterization practices.
What is the operational “infringement map” across the six claims?
Claim chart style mapping
| Claim |
Required condition |
Route limitation |
Active identity |
Dose ceiling |
Biomarker limitation |
Formulation limitation |
| 1 |
Mammal with AML |
Oral |
Formula (VII) or salt |
Up to 150 mg/day |
None |
None |
| 2 |
AML with deregulated FLT3 activity |
Oral |
Formula (VII) or salt |
Up to 150 mg/day |
Yes |
None |
| 3 |
Incorporates claim 1 |
Oral |
Formula (VII) or salt |
Up to 150 mg/day |
None |
Microemulsion, soft gel, or solid dispersion |
| 4 |
Incorporates claim 3 |
Oral |
Formula (VII) or salt |
Up to 150 mg/day |
None |
Microemulsion |
| 5 |
Incorporates claim 2 and claim 3 |
Oral |
Formula (VII) or salt |
Up to 150 mg/day |
Yes (FLT3) |
Microemulsion, soft gel, or solid dispersion |
| 6 |
Incorporates claim 5 |
Oral |
Formula (VII) or salt |
Up to 150 mg/day |
Yes (FLT3) |
Microemulsion |
How defendants can attempt to design around
At the claim element level, design-around tends to target one of four axes:
- Active identity: avoid formula (VII) compound/salt (hard if the molecule is the drug substance).
- Dose: exceed the “up to 150 mg/day” ceiling (often not feasible if the clinical regimen is fixed).
- Route: use non-oral delivery (but the independent claim is “orally administering”).
- Formulation class: switch from microemulsion/soft gel/solid dispersion to a different oral platform. Claim 3’s triad is broad enough that typical oral dosage forms may still fall within it depending on construction.
What patents and patent families typically surround formula (VII) AML FLT3 programs in the U.S.?
Executive summary: Without a linked bibliographic record in the prompt, an exact cross-patent enumeration for U.S. 7,973,031 cannot be produced here. However, the claims’ structure indicates the estate is likely part of a small-molecule kinase inhibitor patent family with layered protection across:
- compound structure (formula scope),
- salt and stereochemical variants,
- oral bioavailability and formulation technology, and
- method-of-use targeting AML and FLT3-deregulated disease.
What to expect in the related patent landscape (claim-pattern-driven)
Based on the claim language, nearby patents in the same technological family typically include:
- Earlier compound claims defining formula (VII) or close structural analogs.
- Salt formation dependent claims (since claim 1 covers “or a salt thereof”).
- Pharmacokinetic and formulation patents covering microemulsions, solid dispersions, and soft-gel delivery.
- Method-of-use patents for FLT3-driven AML subsets and related myeloid malignancies.
Key estate feature: This patent protects how the compound is used, not just what it is.
When does exclusivity end for U.S. method-of-use coverage like U.S. 7,973,031?
Short answer: Exclusivity timing depends on the patent term and any statutory adjustments/extension tied to the Orange Book listing for the relevant NDA. The prompt provides no jurisdictional filing or grant/term data beyond the patent number, so a timeline cannot be rendered without risking inaccuracy.
What matters for calculating legal end dates
- Patent filing date (20-year term from earliest effective filing, subject to adjustments)
- U.S. patent grant date
- Patent term adjustment (PTA)
- Possible patent term extension (PTE) tied to FDA approval for the marketed product
- Terminal disclaimer status (if any)
- Whether additional continuation patents exist with later expiration
What Orange Book status would this patent likely have if tied to an NDA for an oral FLT3 AML drug?
Short answer: If U.S. 7,973,031 is listed in the FDA Orange Book, it will likely appear under method-of-use covering the relevant NDA drug product, with possible corresponding drug substance identity matching formula (VII). Orange Book listings usually reflect:
- NOC status for the reference product, and
- the claiming patent mapped to label text.
Limitation: No Orange Book listing details were provided in the prompt, so an exact listing status cannot be stated.
How strong is the patent’s enforceability based on claim architecture?
Short answer: Enforceability is supported by (i) a clear compound definition (formula VII with stereochemical specificity), and (ii) explicit route, dose ceiling, and formulation category limitations in dependent claims. The main litigation risk areas typically center on claim construction for “formula (VII),” “up to 150 mg per day,” and whether accused products fall within the formulation archetypes (microemulsion/soft gel/solid dispersion) and oral administration timing/dosing.
Key construction-sensitive terms
- “compound of formula (VII)” plus stereochemistry and ring system specificity
- “or a salt thereof” (salt type may become a dispute)
- “therapeutically effective amount” (often construed broadly, but still tied to clinical dosing)
- “up to 150 mg per day” (ceiling language can narrow or complicate design-around)
- “microemulsion” (technical definition; may depend on particle size and composition, plus oral form characterization)
- “solid dispersion” and “soft gel” (formulation taxonomy)
Which generic entry risks exist if a competitor challenges the same active in AML?
Short answer: The independent method claim creates a risk for any challenger whose product:
- is an oral equivalent delivering the claimed formula (VII) at ≤150 mg/day, and
- is used in AML treatment practices that match the label or inferred off-label uses in litigation evidence,
- and, for narrower claims, uses microemulsion/soft gel/solid dispersion (and optionally FLT3-deregulated disease stratification).
Risk escalation scenario: If a competitor launches an oral formulation that is a microemulsion and markets it for FLT3-deregulated AML, claim 6 is a direct target.
How does U.S. 7,973,031 compare with broader AML FLT3 method-of-use patents (scope trade-offs)?
Short answer: Compared with method patents that only require “FLT3 inhibitor” without a specific structural identity, U.S. 7,973,031 is narrower because it locks in the specific formula (VII). Compared with patents that claim only composition or only one dosage form, it adds enforceable breadth through:
- oral route,
- a dose cap, and
- multiple oral formulation classes.
Commercial exposure: what product positioning could trigger the highest infringement probability?
Short answer: The highest probability occurs where a marketed oral FLT3 AML therapy is formulated as a microemulsion and is prescribed to patients with FLT3 deregulated activity, within a regimen that fits ≤150 mg/day, using a drug substance that is formula (VII).
What to check in commercialization records (litigation-relevant)
- Labeled indication language for AML and FLT3 stratification
- Formulation description for the commercial dosage form
- Dosage regimen tables showing daily mg
- FDA labeling references describing microemulsion or related formulation attributes
Key Takeaways
- U.S. 7,973,031 is a method-of-treatment patent anchored to oral administration of a specific stereochemically defined compound of formula (VII) (and salts) in AML.
- Claim 1 is broad across AML but requires oral dosing up to 150 mg/day of formula (VII).
- Claims 2, 5, and 6 add a biomarker qualifier: FLT3 deregulated receptor tyrosine kinase activity.
- Claims 3–6 protect multiple oral delivery modalities: microemulsion, soft gel, and solid dispersion, with microemulsion emphasized in claims 4 and 6.
- The core infringement pathway is use + patient disease + oral dosing + compound identity + (for dependent claims) formulation type.
FAQs
- What does “up to 150 mg per day” mean for designing a non-infringing AML dosing regimen?
- How do courts typically construe “microemulsion” in pharmaceutical method-of-use claims?
- Does “or a salt thereof” expand infringement exposure to different counterions for the same API?
- If a product treats FLT3-mutant AML but the label does not use “deregulated FLT3 activity,” does claim 2 still apply?
- What evidence is usually used to prove that an accused product was administered “orally” in a claimed formulation form (microemulsion vs solid dispersion)?
References (APA)
- United States Patent 7,973,031.
